Market closed

Denali Therapeutics/$DNLI

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Ticker

$DNLI
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
South San Francisco, United States

Employees

390
Website
www.denalitherapeutics.com

DNLI Metrics

BasicAdvanced
$2.8B
-
-$2.73
1.39
-

$2.8B

1.39

$31.56

$14.56

905K

9.976

9.621

3.374

3.983

-5,125.04%

-23.81%

-35.09%

2.14

2.14

-8.161

-100.00%

198.65%

126.24%

What the Analysts think about DNLI

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.

DNLI Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DNLI Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

DNLI News

AllArticlesVideos
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Seeking Alpha·5 days ago
Denali Therapeutics ALS drug fails in mid-stage trial

Denali Therapeutics ALS drug fails in mid-stage trial

Reuters·1 week ago
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DNLI

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Denali Therapeutics stock?

Denali Therapeutics (DNLI) has a market cap of $2.8B as of January 15, 2025.

What is the P/E ratio for Denali Therapeutics stock?

The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of January 15, 2025.

Does Denali Therapeutics stock pay dividends?

No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Denali Therapeutics dividend payment date?

Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.

What is the beta indicator for Denali Therapeutics?

Denali Therapeutics (DNLI) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.